Kezar Life Sciences, Inc.: Business Overview, Financials & Competitive Analysis
Kezar Life Sciences, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Selective exposure to immune-mediated disease therapies with potential for significant upside if clinical programs succeed, offset by execution risk typical of early-stage biotech. Early-stage clinical biotech with promising first-in-class mechanisms but facing typical development risks and recent workforce restructuring. Lead candidate has progressed through early trials, though clinical.
What is Kezar Life Sciences, Inc.'s industry? Kezar Life Sciences, Inc. (kezarlifesciences.com) operates in Biopharmaceuticals - Small Molecule Therapeutics. AskCyborg classifies Kezar Life Sciences, Inc. under Biopharmaceuticals - Small Molecule Therapeutics in its company registry.
Kezar Life Sciences is a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company is developi...
Cyborg Score thesis
Selective exposure to immune-mediated disease therapies with potential for significant upside if clinical programs succeed,...
Read the full analyst-debate transcript →Get the Latest Kezar Life Sciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeKezar Life Sciences, Inc. Overview
Pro stress-test →Kezar Life Sciences is a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company is developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins.
Strategic Profile
Pro stress-test →The lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The company is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Competitive Landscape
Pro stress-test →Kezar competes in the immunoproteasome inhibitor and autoimmune disease treatment space against larger pharmaceutical companies and biotech firms developing competing therapies. Its differentiation lies in first-in-class mechanisms and focused pipeline targeting underserved autoimmune indications.
Industry Context
Kezar Life Sciences, Inc. operates in Biopharmaceuticals - Small Molecule Therapeutics.
Key facts
Founded: 2015 · Headquarters: South San Francisco, California